Glaukos (GKOS) Stock May Be 33% Undervalued As It Joins A New Index

Glaukos has seen its share price surge in recent years, which puts a spotlight on a simple question for anyone looking at the stock today: Does the current valuation line up with the cash flows that the business is expected to generate over time, based on a Discounted Cash Flow (DCF) view of intrinsic value?

• Over the past 5 years, Glaukos has delivered a 421.3% share price return, which raises the stakes on whether the recent run is supported by the company’s cash flow profile.
• The planned move from the S&P SmallCap 600 to the S&P MidCap 400 may support higher liquidity and a broader investor base, which can influence how the market prices Glaukos relative to its future cash generation.
• What if you looked at Glaukos through its sales instead? See why Glaukos's 21.1x P/S tells a different valuation story.

The issue now is whether Glaukos's current share price fairly reflects its projected cash flows when viewed through an intrinsic value lens.

If you want a wider hunting ground while you weigh Glaukos at $246.03 and its recent index move, start with a focused screen of 32 high quality undervalued stocks.

Does Glaukos Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) model here takes Glaukos’ expected future free cash flows and brings them back to today’s dollars. Glaukos currently produces last twelve month free cash flow of about $35.5 million, and the model then assumes that this ramps up over time, with analyst forecasts and extrapolations pointing to growing free cash flow rather than a flat or shrinking profile.

Those cash flow estimates, when discounted, lead to a total intrinsic value that the model indicates is above the current share price of $246.03. Because Glaukos is moving from the S&P SmallCap 600 into the S&P MidCap 400 as of November 2026, that index shift could broaden the shareholder base. This, in turn, might help close some of the gap the DCF sees between the stock and the value implied by its projected cash generation. Find out what Glaukos could be worth using our Discounted Cash Flow (DCF) estimate.

The Glaukos Narrative: What Would Justify Today's Price?

Glaukos' valuation question sets up the role of Simply Wall St Narratives, which sit on the Community page and spell out what would need to happen to growth, margins and earnings for the stock to justify a meaningfully higher or lower price than today. Rather than relying on a single multiple or DCF output, each Narrative sets out the assumptions behind its fair value so you can later compare them with the actual results as they come through.

One of the top narratives on Glaukos: 9% undervalued

This is the bullish analyst Narrative on Simply Wall St, built on the most optimistic analyst price target and forecasts, not one person's view.

"The current valuation suggests investors are paying for a durable, high-margin growth narrative in Glaukos that reflects expectations for execution across glaucoma, corneal health and early retinal pipeline initiatives..."

Discover why this Narrative puts Glaukos at 9% undervalued.

One more Glaukos signal to weigh before you make a move

Valuation is only part of the picture for Glaukos, and the checks have highlighted recent share sales by people on the inside, with the specific sellers, volumes and potential read-throughs still for you to review. See the recent insider selling flagged for Glaukos.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com